Compare e l f Beauty Inc (ELF) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
e l f Beauty Inc vs Recursion Pharmaceuticals Inc — how do they compare? e l f Beauty Inc trades at $109.53 (market cap $6.25B), while Recursion Pharmaceuticals Inc trades at $4.29 (market cap $2.14B). The key difference: e l f Beauty Inc is far larger — about 2.9× Recursion Pharmaceuticals Inc's market cap, and e l f Beauty Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold e l f Beauty Inc for 25 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| ELF | RXRX | |
|---|---|---|
Market Cap | $6.25B | $2.14B |
Volume | 1,099,552 | 30,789,535 |
Sector | Consumer Staples | Health |
52-Week High | $144.97 | $6.79 |
52-Week Low | $49.57 | $2.84 |
Typical Hold Time | 25 Days | 23 Days |
Enterprise Value | $6.84B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ELF Beauty trades at $109.12, up 3.89% today, and is near its R3 resistance level of $109. The stock shows strong technical momentum with bullish moving averages, though RSI levels above 70 indicate potential overbought conditions. Fundamentally, the company reported revenue of $1.31 billion in 2025 with a net income of $112.09 million, and recent earnings beats in Q4 2025, Q1 2026, and Q2 2026 highlight operational strength. Expansion into Europe via Sephora for the rhode brand and marketing initiatives like the 'Mirror Mix' album signal aggressive growth strategies.
The outlook for ELF is positive given earnings momentum and international expansion, but the high P/E ratio of 108.12 poses valuation risks. Analyst consensus is a 'Buy' with a price target of $95.91, below the current price, suggesting limited near-term upside. Key risks include competitive pressures in the beauty sector and sensitivity to consumer spending trends. Institutional buying activity, such as State Street Corp's increased stake, supports confidence in long-term growth.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About e l f Beauty Inc
e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
